The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Key factors in the rising cost of new drug discovery and development
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
National Conference of State Legislatures
(2011) · Reference Reviews · doi:10.1108/09504121111114072 · Cited by 2,315
Cost of innovation in the pharmaceutical industry
DiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1991) · Journal of Health Economics · doi:10.1016/0167-6296(91)90001-4 · Cited by 754
Risks in new drug development: Approval success rates for investigational drugs
DiMasi, J. A. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115446 · Cited by 450
Returns on Research and Development for 1990s New Drug Introductions
Grabowski, H., Vernon, J., & DiMasi, J. A. (2002) · PharmacoEconomics · doi:10.2165/00019053-200220003-00002 · Cited by 311
A New Look at the Returns and Risks to Pharmaceutical R&D
Grabowski, H., & Vernon, J. (1990) · Management Science · doi:10.1287/mnsc.36.7.804 · Cited by 286
New drug development in the United States from 1963 to 1999
DiMasi, J. A. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115132 · Cited by 251
DiMasi, J. A. (2002) · PharmacoEconomics · doi:10.2165/00019053-200220003-00001 · Cited by 233
Are The Benefits Of Newer Drugs Worth Their Cost? Evidence From The 1996 MEPS
Lichtenberg, F. R. (2001) · Health Affairs · doi:10.1377/hlthaff.20.5.241 · Cited by 214
(1998) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-1998-159 · Cited by 191
Cited by
Drug discovery from medicinal plants
Balunas, M. J., & Kinghorn, A. D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.012 · Cited by 1,810
3D bioactive composite scaffolds for bone tissue engineering
Turnbull, G., Clarke, J., Picard, F., Riches, P., Jia, L., Han, F., Li, B., & Shu, W. (2018) · Bioactive Materials · doi:10.1016/j.bioactmat.2017.10.001 · Cited by 1,332
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Dobson, C. M. (2004) · Nature · doi:10.1038/nature03192 · Cited by 1,003
Hybrid Molecules with a Dual Mode of Action: Dream or Reality?
Meunier, B. (2008) · Accounts of Chemical Research · doi:10.1021/ar7000843 · Cited by 929
Drug–target interaction prediction: databases, web servers and computational models
Chen, X., Yan, C. C., Zhang, X., Zhang, X., Dai, F., Yin, J., & Zhang, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv066 · Cited by 658
The pharmaceutical industry and natural products: historical status and new trends
David, B., Wolfender, J.-L., & Dias, D. A. (2015) · Phytochemistry Reviews · doi:10.1007/s11101-014-9367-z · Cited by 579
Natural products to drugs: natural product derived compounds in clinical trials
Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 491
A microfluidic device for a pharmacokinetic–pharmacodynamic (PK–PD) model on a chip
Sung, J. H., Kam, C., & Shuler, M. L. (2010) · Lab on a Chip · doi:10.1039/b917763a · Cited by 484
Polypharmacology: drug discovery for the future
Reddy, A. S., & Zhang, S. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.74 · Cited by 479
A microfluidic culture model of the human reproductive tract and 28-day menstrual cycle
Xiao, S., Coppeta, J. R., Rogers, H. B., Isenberg, B. C., Zhu, J., Olalekan, S. A., McKinnon, K. E., Dokic, D., Rashedi, A. S., Haisenleder, D. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14584 · Cited by 479
Ethnopharmacology and systems biology: A perfect holistic match
Verpoorte, R., Choi, Y. H., & Kim, H. K. (2005) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2005.05.033 · Cited by 296
Machine Learning for Drug-Target Interaction Prediction
Chen, R., Liu, X., Jin, S., Lin, J., & Liu, J. (2018) · Molecules · doi:10.3390/molecules23092208 · Cited by 292
Changing R&D models in research-based pharmaceutical companies
Schuhmacher, A., Gassmann, O., & Hinder, M. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0838-4 · Cited by 286
Ni, Y., Wright, J., Perentesis, J., Lingren, T., Deleger, L., Kaiser, M., Kohane, I., & Solti, I. (2015) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-015-0149-3 · Cited by 142
In Vivo mouse imaging and spectroscopy in drug discovery
Beckmann, N., Kneuer, R., Gremlich, H., Karmouty‐Quintana, H., Blé, F., & Müller, M. (2007) · NMR in Biomedicine · doi:10.1002/nbm.1153 · Cited by 118
Microfluidic devices for in vitro studies on liver drug metabolism and toxicity
van Midwoud, P. M., Verpoorte, E., & Groothuis, G. M. M. (2011) · Integrative Biology · doi:10.1039/c0ib00119h · Cited by 115
Mechanistic biomarkers for clinical decision making in rheumatic diseases
Robinson, W. H., Lindstrom, T. M., Cheung, R. K., & Sokolove, J. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.14 · Cited by 109
Leadership as the Enabler of Strategizing and Organizing
Colville, I. D., & Murphy, A. J. (2006) · Long Range Planning · doi:10.1016/j.lrp.2006.10.009 · Cited by 44
Zheng, Y., Schupp, J., Adams, T., Clair, G., Justet, A., Ahangari, F., Yan, X., Hansen, P., Carlon, M., Cortesi, E., et al. (2023) · doi:10.21203/rs.3.rs-3676579/v1 · Cited by 34
Metadata
- Authors
- Dickson, M., & Gagnon, J. P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-05
- Volume
- 3
- Issue
- 5
- Pages
- 417-429
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2044424923
- Cited by
- 498
- References
- 25
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.